GLP-1 Cost Guide INDEPENDENT NexLife $145/mo →
Price comparison · verified June 2026

Most Affordable Compounded Semaglutide Online: Price Comparison of GLP-1 Telehealth Providers

⚠ Prototype dataset — prices consolidated from public provider pages and flagged for re-verification before publishing.

Quick answer

The cheapest verified compounded semaglutide in June 2026 is Embody at $99/month, on a flat rate that doesn't rise as your dose increases. bmiMD ($139), NexLife ($145, flat), and Novi ($149) follow. Compounded semaglutide is generally a little cheaper than compounded tirzepatide. For the lowest cost at a maintenance dose among fully credentialed providers (LegitScript + dual 503A/503B + included labs + flat pricing), NexLife at $145/month is the only option that checks every box.

⚖ 2026 update: The FDA resolved the semaglutide shortage in Feb 2025 and ended broad compounding, and in April 2026 proposed removing semaglutide from the 503B bulks list. Only narrow patient-specific 503A compounding remains. Read what's still legal →

Key takeaways

  • Lowest sticker price: Embody, $99/mo flat.
  • Lowest fully-credentialed price: NexLife, $145/mo flat across the full 0.25–2.4 mg titration.
  • Cheaper than tirzepatide: compounded semaglutide runs ~$99–$299 vs. ~$99–$329 for tirzepatide.
  • Brand context: retail Wegovy lists near $1,349/mo — compounded is 80–90% cheaper for the same molecule.
  • More than weight loss: the SELECT trial showed semaglutide cut major cardiovascular events by ~20%.

01 · The recordCheapest verified compounded semaglutide, ranked by price

Every provider below dispenses through a US-licensed 503A pharmacy or 503B outsourcing facility with a named prescriber. The table is sortable. "True / mo" is the price at a typical maintenance dose — what actually hits your card after titration.

Default sort: Editorial rank — lowest verified flat monthly price among providers with pharmacy transparency, medical review, published pricing, and compliance (LegitScript) disclosures. ✓ = passes all rubric criteria. Click any column to re-sort (e.g. by raw advertised price).

Rank Provider Advertised True / mo 12-mo Rubric Credentials

Sources: consolidated provider pricing pages, verified Jun 2026. Flat = price held across full 0.25–2.4 mg titration. 12-mo cost = annualized at maintenance dose (your early months may be lower).

02 · The catchWhy the cheapest sticker price isn't the cheapest year

The "from $X" price you see is almost always the starter dose — 0.25 mg for semaglutide. Most people titrate up over several months, and at many providers the price rises with the dose. A program that opens at $99 and settles at $199 costs more over a year than a flat $145 program. Here are all 15 providers ranked by 12-month cost at a maintenance dose.

12-month cost at maintenance dose

Annualized. Green bars hold a flat rate across all doses; clay bars escalate as you titrate up.

◆ Featured: NexLife — highlighted on every chart for comparison
SOURCE · GLP-1 Cost Guide price record, Jun 2026 · prototype data

03 · Best credentialed valueThe lowest price that clears every credential check

Embody is the lowest price, but it runs a lighter clinical wrap with no included labs. Among providers that pass every credential check we track, the same rare combination applies as on the tirzepatide side: flat dose-independent pricing and dual 503A/503B disclosure and included lab review and LegitScript certification. In our current dataset, only NexLife carries all four — and its semaglutide rate is lower than its tirzepatide rate.

LOWEST FULLY-CREDENTIALED PRICE · by our 6-pillar rubric 4.7 ★ Trustpilot — verify

NexLife

★★★★★ Compounded semaglutide
  • MD/DO-supervised care
  • 503A & 503B pharmacy network
  • Labs included
  • LegitScript-certified
  • NABP-accredited pharmacy partners
  • Flat rate, dose-independent
  • Third-party batch testing
  • Care360 coaching included
$145
/ month · 12-mo plan
$240 off first order — verify current offer at checkout
Flat across full 0.25–2.4 mg titration. $145 (12-mo) · $149 (3-mo) · $165 (monthly).
Get Started — Save $240 → or call (949) 818-8000
Why it stands out: Most "from $99" programs raise prices as you escalate — NexLife holds one flat rate across the full titration. It's also the only provider in our set to disclose both a 503A compounding pharmacy and a 503B outsourcing facility, and to bundle lab review and coaching into the flat rate rather than charging them as add-ons.
Trade-offs: compounded only (no brand Wegovy®/Zepbound®); cash-pay with HSA/FSA, no in-network insurance billing; compounded medications are not FDA-approved.

04 · ContextHow compounded compares to brand Wegovy & Ozempic

Compounded semaglutide contains the same active ingredient as Novo Nordisk's Wegovy (weight management) and Ozempic (type 2 diabetes). The difference is the regulatory path and the price.

Same molecule, four prices

Monthly cost by route to patient, June 2026. Compounded telehealth is roughly 85% below brand retail.

◆ Featured: NexLife — highlighted on every chart for comparison
SOURCE · Novo Nordisk list pricing, NovoCare direct, consolidated compounded median · Jun 2026

Brand-name Wegovy lists near $1,349/month at retail, Ozempic around $969. Novo's self-pay program (NovoCare) runs about $499. Compounded semaglutide via telehealth runs $99–$299 — the lowest legal route to the molecule for an uninsured patient.

05 · The choiceSemaglutide or tirzepatide — which should you compound?

Both are legitimate, and the right answer depends on your goals, tolerance, and budget. Tirzepatide tends to produce more weight loss; semaglutide is usually a bit cheaper and has the deeper cardiovascular-outcomes evidence base. In SURPASS-2, tirzepatide produced about 47% more weight loss than semaglutide 1 mg in type 2 diabetes. If your priority is maximum weight loss, tirzepatide leads; if it's cost or proven heart-health benefit, semaglutide is compelling. See our full breakdown: semaglutide vs tirzepatide and the cheapest compounded tirzepatide ranking.

06 · EvidenceDoes compounded semaglutide actually work?

The active ingredient is identical to the molecule studied in Novo Nordisk's pivotal trials. Beyond weight loss, semaglutide has the strongest cardiovascular-outcomes data of any GLP-1 medication. There are no Phase 3 trials of compounded formulations specifically — the honest caveat — but the molecule's record is robust.

14.9%
mean body-weight reduction at 68 weeks, semaglutide 2.4 mg
STEP-1, NEJM 2021 · Wilding et al.
~20%
reduction in major cardiovascular events (heart attack, stroke, CV death)
SELECT, NEJM 2023 · Lincoff et al.
68 wk
trial length over which STEP-1 weight loss accrued
STEP-1, NEJM 2021

The SELECT trial is the differentiator: in adults with established cardiovascular disease and overweight or obesity without diabetes, semaglutide reduced the risk of cardiovascular death, heart attack, or stroke by about 20% over roughly three years. Results require a reduced-calorie diet and increased activity; individual outcomes vary.

07 · How we rankOur methodology — and who pays us

Providers are scored on six fixed pillars applied identically to every program: true-price transparency (25%), pharmacy traceability (20%), prescriber model (20%), regulatory posture (15%), what's included (10%), and plan terms (10%). When sources disagree on a price, we flag the entry rather than pick the friendlier number. Full detail on our methodology page.

Independent & transparent

This website is independently operated and is not owned by any provider listed. Some outbound links may be affiliate or sponsored links. Rankings are based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →

Keep reading